FIELD: antibodies.
SUBSTANCE: invention is related to new molecules of bispecific antibodies that bind CD3δε and BCMA, capable of activating immune effector cells, and their use in the diagnosis and/or treatment of various diseases.
EFFECT: invention makes it possible to obtain bispecific antibodies for therapeutic use to support antitumor effects while simultaneously reducing the release of proinflammatory cytokines.
25 cl, 10 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2779489C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| ANTIBODIES AGAINST GUCY2c AND THEIR USE | 2019 |
|
RU2812113C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| TRISPECIFIC BINDING MOLECULES FOR TREATING VIRAL HEPATITIS B INFECTION AND BOUND STATES | 2016 |
|
RU2733496C2 |
| MULTIMERIZATION TECHNOLOGIES | 2014 |
|
RU2714733C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
